Theralase® Releases 2Q2025 Financial Statements

On August 28, 2025 Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses reported it has released the Company’s unaudited condensed consolidated interim 2Q2025 financial statements ("Financial Statements") (Press release, Theralase, AUG 28, 2025, View Source [SID1234655555]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Theralase will be hosting a conference call on Wednesday, September 3rd at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending June 30th, 2025. Questions are welcome. To ensure we have time to review and properly address them during the call, please send them in advance to [email protected].

Zoom Meeting Link: View Source
Webinar ID: 872 0348 0163
Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom
An archived version will be available on the website following the conference call.

Financial Highlights

For the six-month period ended June 30, 2025 versus June 30, 2024:

Total revenue increased 12% to $310,933 from $276,401
Cost of sales decreased 4% to $178,966 (58% of revenue) from $186,324 (67% of revenue)
Gross margin increased 47% to $131,967 (42% of revenue) from $90,077 (33% of revenue)
Selling expenses decreased 5% to $139,011 from $145,915
Administrative expenses increased 10% to $995,333 from $907,378, driven primarily by increases in general and administrative expenses, administrative salaries and stock-based compensation
Research and development expenses increased 1% to $1,460,447 from $1,450,086, reflecting increased activity to support Study II progress
Net loss for the period increased 1% to $2,423,235 from $2,400,461. This included $471,174 in non-cash charges such as amortization and stock-based compensation.
Operational Highlights

Private Placements:

On April 14, 2025, the Company completed a non-brokered private placement, issuing 1,995,829 units at $0.21 per unit for gross proceeds of $419,124. Each unit included one common share and one non-transferable common share purchase warrant exercisable at $0.32 for five years.
On June 17, 2025, the Company completed a non-brokered private placement, issuing 2,855,000 units at $0.20 per unit for gross proceeds of $571,000. Each unit included one common share and one non-transferable common share purchase warrant exercisable at $0.30 for five years.
On July 28, 2025, the Company completed a non-brokered private placement, issuing 3,363,134 units at $0.20 per unit for gross proceeds of $672,627. Each unit included one common share and one non-transferable common share purchase warrant exercisable at $0.30 for five years.
Warrant Extension:

On June 26, 2025, the Company extended the expiry date of 4,800,000 warrants, all of which are exercisable at $0.35 per share. The warrants were issued on June 30, 2023, pursuant to a private placement involving the issuance of 4,800,000 units of the Company. The new expiry date of the warrants is June 30, 2028.

The Company continues to explore additional equity and non-dilutive funding opportunities to support its clinical and commercial milestones.

Study II Update:

As of August 26, 2025:

86 patients have been treated with the primary Study Procedure, representing approximately 96% of the total targeted enrollment of 90 patients.
70 patients have completed the clinical study being assessed at all assessment visits or have been prematurely removed from the clinical study by the principal investigator for lack of response
16 additional patients are pending study completion.
Interim clinical results indicate:

61.4% (43/70) patients achieved a Complete Response ("CR") at any point in time
70% (49/70) achieved a Total Response (CR + Indeterminate Response ("IR")) (IR = negative cystoscopy with positive urine cytology, without a confirmatory bladder biopsy)
At the 450-day assessment, 39.5% (17/43) of patients maintained a CR, indicating strong durability of treatment effect.
Theralase remains on track to complete enrollment in 3Q2025, with data lock targeted for 4Q2026 and regulatory submissions expected in 4Q2026.

For additional information, please refer to the Company’s Management’s Discussion and Analysis ("MD&A") available at www.sedarplus.ca.

About Ruvidar:
Ruvidar (TLD-1433) is a small molecule, able to be activated by light, radiation, sound and other drugs, intended for the safe and effective destruction of cancer, bacteria and viruses.

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

On August 28, 2025 Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, reported that its management expects to participate in the following investor conferences in September (Press release, Cartesian Therapeutics, AUG 28, 2025, View Source [SID1234655554]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A fireside chat at the Cantor Global Healthcare Conference 2025 at 11:30 a.m. ET on Thursday, September 4, 2025
A fireside chat at Morgan Stanley’s 23rd Annual Healthcare Conference at 4:05 p.m. ET on Tuesday, September 9, 2025
A presentation at the H.C. Wainwright 27th Annual Global Investment Conference at 8:30 a.m. ET on Wednesday, September 10, 2025
Live webcasts of the fireside chats and presentation are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

On August 28, 2025 Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, reported it will participate in two investor conferences next month. CEO Jared Kelly will be meeting with institutional investors at the H.C. Wainwright 27th Annual Global Investment Conference and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference (Press release, Oncolytics Biotech, AUG 28, 2025, View Source [SID1234655553]). Additional details for both of these events can be found below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: Tuesday and Wednesday, September 9 & 10, 2025
Location: Lotte New York Palace Hotel, New York, NY

Event: Lake Street Capital Markets 9th Annual Best Ideas Growth Conference
Date: Thursday, September 11, 2025
Location: The Yale Club, New York, NY

Company management will be participating in one-on-one investor meetings at the conferences. To schedule a meeting, please submit a request on the conference website, contact your H.C. Wainwright or Lake Street Capital Markets representative, or email [email protected].

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

On August 28, 2025 Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, reported it will participate in two investor conferences next month. CEO Jared Kelly will be meeting with institutional investors at the H.C. Wainwright 27th Annual Global Investment Conference and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference (Press release, Oncolytics Biotech, AUG 28, 2025, View Source [SID1234655553]). Additional details for both of these events can be found below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: Tuesday and Wednesday, September 9 & 10, 2025
Location: Lotte New York Palace Hotel, New York, NY

Event: Lake Street Capital Markets 9th Annual Best Ideas Growth Conference
Date: Thursday, September 11, 2025
Location: The Yale Club, New York, NY

Company management will be participating in one-on-one investor meetings at the conferences. To schedule a meeting, please submit a request on the conference website, contact your H.C. Wainwright or Lake Street Capital Markets representative, or email [email protected].

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

On August 28, 2025 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, reported it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 16,216,216 shares of common stock of the Company originally issued in June 2025 at an exercise price of $0.37 per share (Press release, Moleculin, AUG 28, 2025, View Source [SID1234655552]). The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-287727). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $6.0 million, before deducting financial advisory fees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roth Capital Partners is acting as the Company’s financial advisor for this transaction.

In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 64,864,864 shares of common stock, at an exercise price of $0.55 per share and will be exercisable upon shareholder approval and for a term of five years from the date of shareholder approval.

The transaction is expected to close on or about August 28, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "1933 Act") and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.